ABSTRACT Interleukin (IL) -33 has been identified as a member of the IL-1 family. Members of the IL-1 family have been reported to be involved in the regulation of energy homeostasis and glucose metabolism. Homozygous transgenic mutant mice of FLP14 line, that we previously generated, unexpectedly developed mature-onset obesity and diabetes. Through genetic investigations, we found that insertion of the transgenes had resulted in complete deletion of the Il33 gene. These obese male homozygous mutant mice exhibited hyperphagia with hyperleptinemia and insulin resistance caused by increased hepatic gluconeogenesis and decreased glucose uptake in skeletal muscle. As a result of examining preobese male homozygous mutant mice to investigate with the exclusion of the effect of obesity, hyperphagia with hyperleptinemina and insulin resistance caused by decreased glucose uptake in skeletal muscle were already observed, but the increased hepatic glucose production was not. To investigate whether the insulin resistance was caused by deletion of the Il33 gene, we treated these preobese homozygous mutant mice with recombinant IL-33 protein and noted a significant improvement in insulin resistance. Thus, insulin resistance in these homozygous mutant mice was caused, at least in part, by IL-33 deficiency, suggesting a favorable role of IL-33 for glucose metabolism in the skeletal muscle.
The random insertion of transgenic fragments into the mouse genome by pronuclear microinjection is potentially mutagenic, and transgene-induced mutations were found in 5%-10% of transgenic mice [1] [2] [3] .
There are examples of the accidental insertion of a transgene into a crucial genomic locus that yielded important information 4, 5 . The present study began with the unexpected observation of the obesity phenotype in homozygous transgenic mutant mice of FLP14 line harboring the Flp recombinase 6 . We characterized the transgene integration site in this mutant mouse and found that the insertion of the transgenes was accompanied by a 124.2-kb deletion at the left end of the transgene and a 38.2-kb inversion and a 4.6-kb deletion at the right end. These mutations included the complete deletion of the Interleukin (Il) 33 gene.
Interleukin (IL) -33 (or IL1F11) has been identified as a functional ligand for the orphan receptor ST2, a member of the IL-1 receptor family 7 . Cytokines of the IL-1 family play an important role in immune regulation and inflammatory processes by inducing the expression of many effector proteins. In addition, members of the IL-1 family, IL-1and IL-18 have been reported to play a favorable role in the regulation of body weight and glucose metabolism [8] [9] [10] . IL-33 also has been shown to be pro-inflammatory in conditions such as autoimmunity 11 and allergy 12 and to be protective in conditions such as obesity [13] [14] [15] , atherosclerosis
In the present study, we examined the glucose homeostasis and genetic profile of the homozygous mutant mice of FLP14 line that unexpectedly exhibited mature-onset obesity. Genetic analysis demonstrated complete deletion of the Il33 gene in these mice, which raised the hypothesis that disappearance of IL-33 causes insulin and leptin resistance in this mutant mouse. To test this hypothesis, we investigated the impact of recombinant IL-33 protein supplementation on the glucose metabolism in the preobese male homozygous mutant mice.
Results
Mature-onset obesity in a homozygous transgenic mutant mouse of FLP14 line. Previously, we reported several transgenic mouse lines of the C57BL/6 strain carrying a Flp recombinase expression vector under the control of the human eukaryotic translation elongation factor 1a promoter 6 ( Fig. S1A ). Among these lines, one homozygous mutant mice of FLP14 line (mutant) showed an obesity phenotype.
The body weights of the male mutant mice started to deviate from those of the male wild-type control (control) mice at 5 months of age and were increased by 13% at 6 months of age ( Fig. 1A and B, left panels).
On the other hand, the body weights of the female mutant mice started to deviate from those of the female control mice at 3 months of age and were markedly increased by 38% at 6 months of age ( Fig. 1A and B, right panels). Gross appearance at sacrifice revealed that the fat mass in mutant mice was higher than that in the control mice (Fig. 1C) . Moreover, marked fatty liver was observed in mutant mice (Fig. 1C ). The weights of liver and visceral white adipose tissue (WAT) were also significantly increased in the mutant mice of both sexes compared with those in the control mice at 5 to 6 months of age (Fig. 1D ).
The obese male mutant mice exhibited leptin and insulin resistances caused by both increased gluconeogenesis in liver and decreased glucose uptake in skeletal muscle. First, to examine the phenotype, the male mutant mice from 5 to 6 months of age were studied as the obese phase. The food intake of the male mutant mice was significantly increased compared with that of the control mice ( Fig.   2A ; left panel). The serum concentrations of leptin, which is an adipocytokine that regulates food intake, were significantly higher in the mutant mice than in the control mice ( Fig. 2A ; center panel). These association of hyperphagia and high leptin concentrations was suggestive of a leptin-resistant condition.
Furthermore, the leptin/weight ratios in the mutant mice were also higher than those in the control mice ( Fig. 2A ; right panel). This result suggest that leptin resistance of the mutant mice was not a secondary induced by obesity induced but was primary. The serum cholesterol levels of the mutant mice were significantly higher than those of the control mice, although the serum triglyceride (TG) levels were indistinguishable ( Fig. 2B ; left and center panels). The serum adiponectin, which is an adipocytokine that regulates glucose and lipid metabolism, acting against diabetes and atherosclerosis, levels of the mutant mice were significantly lower than those of the control mice ( Fig. 2B; right panel) . The TG contents of both the muscle and the liver in mutant mice were significantly increased compared with those in control mice (Fig. 2C) . The mutant mice exhibited elevated fasting blood glucose and serum insulin levels compared with those of control mice (Fig. 2D) . These results were suggestive of an insulin-resistant condition.
Therefore, we carried out hyperinsulinemic-euglycemic clamp studies to access the insulin resistance and to investigate whether the cause of the insulin resistance of the obese mutant mice is in the skeletal muscle and/or in the liver. In the hyperinsulinemic-euglycemic clamp study, the exogenous glucose infusion rates (GIRs) were significantly decreased in the mutant mice (Fig. 2E, left panel) . Furthermore, the mutant mice exhibited not only a significant increase in the endogenous glucose productions (EGPs) but also a significant decrease in the rate of glucose disappearance (Rd) (Fig. 2E , center and right panels). These results suggest that the obese mutant mice had insulin resistance caused by both increased hepatic glucose productions and decreased glucose uptakes by the skeletal muscle. These findings suggest that the genetic mutations of the mutant mice lead to obesity caused by hyperphagia, dyslipidemia, fatty liver and muscle, and diabetes with systemic insulin resistance.
The preobese male mutant mice already exhibited leptin and insulin resistances in skeletal muscle, but not in liver. Next, to exclude the effect of obesity, the young 'preobese' male mutant mice from 2 to 3 months of age who were the same weight as the control mice were studied. The food intake of the mutant mice was significantly increased compared with that of the control mice ( Fig. 3A ; left panel). The serum concentrations of leptin were significantly higher in the mutant mice than those in the control mice ( Fig. 3A ; right panel). To evaluate the energy expenditure, we investigated the oxygen consumption and found that it was indistinguishable between the mutant and control mice (Fig. 3B ). These findings suggest that the preobese mutant mice already had leptin resistance that was independent of obesity, and that obesity was not due to reduced energy expenditure but due to hyperphagia caused by leptin resistance. The serum cholesterol and TG levels of the preobese mutant mice were significantly higher than those of the control mice ( Fig. 3C ; left and center panels). The serum adiponectin levels of the preobese mutant mice were indistinguishable from those of the control mice ( Fig. 3C ; right panel). The TG contents of both the muscle and the liver in mutant mice were not increased compared with those in control mice ( Fig. 3D ; left and center panels), and the weight of WAT in each genotype was indistinguishable ( Fig. 3D ; right panel). These results and previous experiments of obese mutant mice suggest that the decrease of serum adiponectin levels and fatty muscle and liver observed in the obese mutant mice were induced by obesity. However, importantly, the preobese mutant mice already exhibited elevated fasting blood glucose and serum insulin levels compared with those of the control mice (Fig. 3E) . These results were suggestive of an insulinresistant condition in the preobese mutant mice. We then next performed hyperinsulinemic-euglycemic clamp studies in the preobese mutant and control mice to investigate the insulin resistance of muscle and liver. We found that the GIRs were significantly decreased in the preobese mutant mice as compared to the control mice (Fig. 3F , left panel). Although the EGPs were indistinguishable between the mutant mice and control mice (Fig. 3F , center panel), the Rd was significantly decreased in the mutant mice as compared to the control mice (Fig. 3F , right panel). These results suggest that preobese mutant mice had insulin resistance caused by decreased glucose uptakes by the skeletal muscle, but the increased hepatic glucose production has not observed yet. To assess insulin signaling in the muscle of the preobese mutant mice, we conducted western blot analyses. Insulin-stimulated tyrosine phosphorylations of insulin receptor substrate-1(IRS-1) and insulin-stimulated phosphorylations of Akt were reduced in the muscle of preobese mutant mice as compared to that of control mice (Fig. 3G ). These findings suggest that the genetic mutations in the mutant mice led to insulin resistance in skeletal muscle, but not in liver, and that this was independent of obesity.
The Il33 gene is completely deleted in mutant mice and recombinant IL-33 protein restored insulin resistance in the muscle of mutant mice. We hypothesized that the phenotype of obesity, and insulin and leptin resistances exhibited in these homozygous mutant mice was caused by transgenic insertional mutagenesis, because homozygous mice of the other five independent transgenic lines were not obese.
Cumulative genotyping of mutant heterozygote crosses revealed that the manner of transgene transmission was consistent with Mendelian inheritance, indicating that the recessive obese phenotype was caused by disruption of a single locus in the genome with transgene insertion.
We used Southern blot analysis to analyze the copy number and structure of the transgene insertion site of the mutant mice. In an analysis of mutant genomic DNA cleaved with KpnI, which cut both ends of the transgene, the tg-3' probe detected two transgene-specific bands: a stronger fragment (~3.4 kb)
corresponding to a transgene expression vector and an additional weaker fragment (~4.0 kb) (Fig. S1B) . A comparison of these hybridization intensities with those of standard transgene expression vectors suggested that approximately 3 copies of the transgene were integrated (Fig. S1B) . In an analysis of mutant genomic DNA cleaved with BglII, which cut the transgene at a single point, the tg-5' probe or tg-3' probe detected two transgene-specific bands in both cases: a stronger expected fragment (~3.4 kb) and an additional weaker fragment (~9.5 kb and ~4.0 kb, respectively) (Fig. S1B) . These results suggest that multiple copies of the transgene were integrated in tandem at a single locus.
We next cloned both the left-and right-flanking genomic sequences into which the transgene had been inserted. By using the basic local alignment search tool (BLAST), we determined that both the left-and right-flanking genomic sequences mapped to the mouse chromosome 19qC1 region containing three genes in the order of Il33, Trpd52l3 and Uhrf2 from centromere to telomere ( We identified 3 candidate genes: the Il33 gene is completely deleted, the Trpd52l3 gene is inverted, and the Uhrf2 gene is inverted and partially deleted. Trpd52l3 is a mouse orthologue of the human tumor protein D52-like protein (TPD52L3 or hD55), which contains a coiled-coil motif and is strongly and uniquely expressed in human adult testis 18 . Uhrf2, which is also called Np95/ICBP90-like RING finger protein (NIRH) ubiquitin ligase, belongs to the ubiquitin PHD RING finger family and might behave as a tumor suppressor protein 19, 20 . IL-33 is a member of the IL-1 cytokine family that induces production of TH2 cytokines 7 , and previous studies have indicated a role for the IL-1 family of cytokines in obesity [8] [9] [10] . Based on this information, we focused on Il33 among the three candidate genes. We confirmed the deficiency of IL-33 mRNA expression in various tissues from mutant mice (Fig. 4C ). As reported previously 7 , high levels of IL-33 mRNA expression could be found in the lung of the control mice.
We next treated the preobese mutant mice with recombinant IL-33 (rIL-33) protein before the insulin tolerance tests and the hyperinsulinemic-euglycemic clamp studies. Although the glucose-lowering effect of insulin was significantly impaired in the preobese mutant mice as compared to the control mice in insulin tolerance tests, the glucose-lowering effect of insulin was significantly restored by intraperitoneal administration of 2 µg of rIL-33 to the mutant mice 1 h before the studies (Fig. 4D ). Similar to this result, in the hyperinsulinemic-euglycemic clamp studies, the GIRs were significantly restored by intravenous administration of 2 µg of rIL-33 to the preobese mutant mice 1 h before the studies ( Fig. 4E ; left panel).
Although the EGPs were indistinguishable between the treated and untreated mutant mice ( (Fig. 4F) . Therefore, the possibility that the phenotype of mutant mice is affected by deletion of Uhrf2 cannot be denied.
Discussion
Here we showed that homozygous transgenic mutant mice of FLP14 line unexpectedly exhibit abnormalities characteristic of metabolic syndrome: obesity, hyperphagia, lipid abnormalities and insulin resistance. In these mutant mice, the insertion of the transgenes was accompanied by the complete deletion of the Il33 gene. A hyperinsulinemic-euglycemic clamp study showed that the insulin resistance of obese male mutant mice was caused by increased hepatic gluconeogenesis and decreased glucose uptake in skeletal muscle. In contrast, preobese male mutant mice also exhibited insulin resistance and decreased glucose uptake in skeletal muscle; but, unlike obese mutant mice, they did not show increased hepatic glucose production. Administration of rIL-33 to the preobese male mutant mice improved insulin resistance and restored glucose uptake in the skeletal muscle, suggesting that insulin resistance in the mutant mice is caused by a deficiency of IL-33 and that IL-33 may play a pivotal role in glucose metabolism.
We identified two other genetic mutations (Fig. 4A ) besides the complete deletion of the IL33 gene in the mutant mice. One mutation is an inversion of Trpd52l3 gene locus. Trpd52l3 is mouse orthologue of the human tumor protein D52-like protein, which is strongly expressed in adult human testis 18 . However, it notes that the expression of Trpd52l3 mRNA in the mutant mice was comparable to the expression in those of the control mice (Fig. 4F) . Another mutation is an inversion and a partially deletion of Uhrf2 gene locus, resulting in no expression of Uhrf2 mRNA in the mutant mice. Uhrf2 is a member of the ubiquitin PHD RING finger family and might act as a tumor suppressor protein 19 . Uhrf2 occupies a central position in the cell cycle network, has the capacity to ubiquitinate both cyclins D1 and E1, and connects the cell cycle machinery, the ubiquitin-proteasome system, and the epigenetic system 20 . To the best of our knowledge, however, no previous reports have indicated a relationship between these two genes and obesity or insulin resistance. Also, the almost complete improvement of insulin resistance after rIL-33 treatment suggests that these two genetic modifications have little impact on glucose metabolism.
The mutant mice in the present study exhibited insulin resistance. In general, the two major mechanisms of insulin resistance are increased hepatic glucose production and decreased glucose uptake in skeletal muscle. The former mechanism appeared to be caused by obesity itself rather than gene mutations in the mutant mice because glucose production in the liver was increased in the obese mutant mice (Fig. 2E ) but not in the preobese mutant mice (Fig. 3F) . Also, serum adiponectin levels were significantly reduced only in the obese mutant mice as compared with the control mice (Fig. 2B , right panel).
Adiponectin directly sensitizes the body to insulin 21,22 , and a reduced serum level of adiponectin might have prompted insulin resistance in the obese mutant mice. Likewise, increased hepatic TG content, which might have also caused insulin resistance [23] [24] [25] [26] , was observed only in the obese mutant mice (Fig. 2C , left panel; Fig. 3D, left panel) . On the other hand, decreased glucose uptake in the skeletal muscle appeared to be caused by genetic mutations independent of obesity because it occurred even in the preobese mutant mice (Fig. 3F ). This insulin resistance in the skeletal muscle was also confirmed at the molecular level (Fig.3G) .
Furthermore, rIL-33 protein restored the decreased glucose uptake of skeletal muscle in preobese mutant mice (Fig. 4E , right panel), suggesting that the lack of IL-33 in the skeletal muscle was the primary cause of insulin resistance in the preobese mutant mice and, at least partly, in the obese mutant mice. In addition, in the control mice, the IL-33 expression level in the skeletal muscle was greater than in the liver (Fig. 4C ).
This result might explain why IL-33 deletion in preobese mutant mice affects glucose metabolism in the skeletal muscle, but not in the liver, in a manner that is independent of obesity.
The mutant mice in the present study developed mature-onset obesity (Fig. 1A ) like other types of mice that are genetically deficient in IL-1 family members; mice deficient in IL-1 receptor I ref9 or IL-18 ref10 .
In addition, IL-33 receptor ST2-deficient mice fed a high-fat diet also develop obesity 13 . Our obese mutant mice also showed increased food intake and leptin levels, indicating leptin resistance 27 . Importantly, we found the leptin levels in relation to body weight were higher in the obese mutant mice as compared with the control mice, whereas there was no such difference in IL-18 knockout mice 10 . Furthermore, leptin resistance also occurred in preobese mutant mice, which had increased food intake and serum leptin levels (Fig. 3A, right panel) . Also, in the preobese mutant mice, the energy expenditure was not increased irrespective of the increased leptin levels (Fig. 3B ). These findings suggest that IL-33 plays a key role in the regulation of body weight and that this regulation is at least partly achieved through leptin resistance.
These findings suggest that hyperphagia induced by leptin resistance leads to a gradual increase in body weight, as the preobese mutant mice exhibited hyperphagia, but no change of energy expenditure. The role of IL-33 on body weight showed in the present study is consistent with the report that IL-33 is negatively associated with the body mass index and body weight in lean and overweight subjects 15 . 32, 33 . Importantly, obesity, insulin resistance and type 2 diabetes are closely associated with chronic inflammation characterized by abnormal cytokine production, increased acute-phase reactants and other mediators, and activation of inflammatory signaling pathways 34, 35 .
Therefore, the metabolic effects of IL-33 showed in the present study may be explained by the alteration of inflammatory conditions 13, 14 . Further investigations of the role of IL-33 are needed to clarify this issue.
Limitations of the present study include the possible influence of the mutations of Trpd5213 and Uhrf2.
In particular, unlike Trpd5213, Uhrf2 was not detected in the mutant mice, suggesting that the lack of this gene product might have affected the results of this study. Studies using recombinant Uhrf2 are needed to further clarify this possibility. Also, we could not explore the underlying mechanisms of how the acute administration of rIL-33 improved insulin resistance and muscular glucose uptake on a molecular level.
The use of IL-33-deficient mice instead of these mutant mice is indispensable for further studies. Lastly, we noted hyperphagia, even in the preobese mutant mice, which might have been caused by leptin resistance and may have affected the results. However, the insulin resistance observed in the preobese mutant mice had almost completely recovered immediately after rIL-33 administration, suggesting that IL-33 deficiency itself, rather than any changes caused by hyperphagia, was the primary cause of insulin resistance in our mutant mouse model.
In conclusion, this study suggests that insulin and leptin resistances in the homozygous transgenic mutant mice of FLP14 line is caused by a deficiency of IL-33 and that IL-33 has the possibility of being assigned a favorable role in glucose metabolism in the skeletal muscle.
Methods
Subjects. The Flp recombinase transgenic mouse line was generated by microinjection of C57BL/6N fertilized eggs with the Flp recombinase expression vector pEF-NFLP (Fig. S1A) , as previously described 6 .
Flp (Wako Pure Chemical Industries Ltd., Osaka, Japan) were assayed by enzymatic methods. Plasma leptin and adiponectin levels were determined with a mouse leptin ELISA kit (R&D Systems, Minneapolis, USA) and a mouse adiponectin ELISA kit (Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan), respectively.
TG contents of the muscle and liver.
For determining the TG content in the muscle and liver, the tissue homogenates were extracted and analyzed as described previously 36 .
Hyperinsulinemic-euglycemic clamp study. Clamp studies were performed as described previously 37 with slight modifications in insulin dose. In these studies, a primed continuous infusion of insulin (Humulin R) was administered (15.0 mU/kg/min for obese mice and 10.0 mU/kg/min for preobese mice). The rate of glucose disappearance (Rd) was calculated according to nonsteady-state equations, and endogenous glucose production (EGP) was calculated as the difference between the Rd and the exogenous glucose infusion rate (GIR) 37 .
Analysis of O2 consumption.
Oxygen consumption was measured by using an O2/CO2 metabolism measurement device (Model MK-5000; Muromachikikai, Tokyo, Japan) as described previously 37 .
Mouse recombinant IL-33 protein treatment study.
We injected 2.0 µg mouse rIL-33 (Adipogen, San Diego, California, USA) or saline as the control intraperitoneally at 1 hour before the insulin tolerance test. In the hyperinsulinemic-euglycemic clamp studies, 2.0 µg rIL-33 protein or saline as the control was administered through the catheters at 1 hour before the studies.
Tissue sampling for insulin signaling pathway study and western blot analysis. Mice were anesthetized after a 16-hour fast, and 0.05 units of human insulin (Humulin R) was injected via the inferior vena cava. After 5 min, the skeletal muscles were removed and immediately frozen in liquid nitrogen.
Western blot analysis was performed as described previously 37 .
Analyses of DNA.
Genomic DNA was digested with KpnI, which cut both ends of the transgene, and hybridized with the 2.1-kb BglII-BamHI fragments from pEF-NFLP (tg-3' probe) as a probe (Fig. S1) . To estimate the copy number of the transgene, the intensity of the hybridizing signals was compared with the intensities of varying amounts of the 3.3-kb NotI fragment from pEF-NFLP as a standard.
To determine whether the transgenes were integrated at a single locus, genomic DNA digested with BglII, which cut the transgene at a single point, was hybridized with the 0.7-kb SalI-BglII fragment from pEF-NFLP (tg-5' probe) and tg-3' probe.
A Genome Walker Universal Kit (Clontech, California, USA) was used to identify the mouse genomic sequences adjacent to transgene integration sites and a breakpoint Analyses of RNA. Total RNA was extracted from various tissues in vivo, and cDNA was synthesized as described previously 36 . mRNA levels were quantitatively analyzed by fluorescence-based reverse transcriptase-PCR. The reverse transcription mixture was amplified with specific primers by using an ABI Prism 7300 sequence detector (Applied Biosystems, California, USA). The primers used for Il33, Trpd52l3, Uhrf2 and cyclophilin were purchased from Applied Biosystems. The relative expression levels were compared by normalization to the expression levels of cyclophilin.
Statistical analyses.
Statistical analyses were performed using JMP Ⓡ Pro for Windows, version 10.0 (SAS Institute Inc., Cary, North Carolina, USA). Data were expressed as mean ± SEM. Differences between two groups were assessed by using unpaired t-tests. Data involving more than two groups were assessed by one-way ANOVA before Tukey-Kramer's post-hoc test as appropriate to correct for multiple comparisons.
All statistical tests were two-tailed. Statistical significance was set at P<0.05.
Data availability.
The dataset generated and analyzed in the current study is available from the corresponding author on reasonable request.
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